Responses
ATRT, PD, tumor, brainstem glioma
ANAPLASTIC ASTROCYTOMA, TUMOR, GLIOBLASTOMA MULTIFORME, WILMS TUMOR, DISEASE, EMBRYONAL RHABDOMYOSARCOMA, GERM CELL TUMOR, ALVEOLAR RHABDOMYOSARCOMA, MEDULLOEPITHELIOMA, ATYPICAL TERATOID/RHABDOID TUMOR OF CNS, CLEAR CELL SARCOMA, OSTEOSARCOMA, EWING SARCOMA
Nineteen patients achieved the threshold metformin exposure defined in the methods section or progressed after initiation of metformin making them evaluable for response, with 16 patients evaluable for best overall response (Figure Swimmer's plot of 26 patients treated on study, with timing of overall best response and disease status at end of protocol therapy shown. AA, anaplastic astrocytoma; ARMS, alveolar rhabdomyosarcoma; ATRT, atypical teratoid/rhabdoid tumor of CNS; BSG, brainstem glioma; CCS, clear cell sarcoma of the kidney; CNOS, CNS tumor not otherwise specified; CNSM, central nervous system medulloepithelioma; CR, complete response; ERMS, embryonal rhabdomyosarcoma; ES, Ewing sarcoma; GBM, glioblastoma multiforme; GCT, germ cell tumor; N/A, not applicable as best overall response was unable to be determined; OS, osteosarcoma; PD, progressive disease; PR, partial response; SD, stable disease; WT, Wilms Tumor.